Moderna falls as co expects delay in FDA approval for flu-COVID combo shot

Shares of vaccine maker Moderna MRNA.O fall 6.1% to $26.81

Co pushes back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza

"It's not directly clear how MRNA will be impacted by HHS (Department of Health and Human Services) requirements for placebo studies for "new" vaccines... Flu will not need placebo per HHS. But overall, changes by HHS bring uncertainty for the landscape and investors" - brokerage Jefferies

MRNA posts Q1 adj loss of $2.52/shr, smaller than Wall Street estimates for a loss of $3.14/shr - LSEG

Co brings in $108 mln in Q1 revenue, slightly ahead of analysts' expectations of $106.2 mln

Including session's move, stock down 33.9% YTD